Milk thistle contains silybin, which is a potential iron chelator. We aimed to determine whether silybin reduced iron absorption in patients with hereditary haemochromatosis. In this crossover study, on three separate occasions, 10 patients who were homozygous for the C282Y mutation in the HFE gene (and fully treated) consumed a vegetarian meal containing 13.9 mg iron with: 200 ml water; 200 ml water and 140 mg silybin (Legalon Forte); or 200 ml tea. Blood was drawn once before, then 0.5, 1, 2, 3 and 4 h after the meal. Consumption of silybin with a meal resulted in a reduction in the postprandial increase in serum iron (AUC ± s.e.) compared with water (silybin 1726.6 ± 346.8 versus water 2988.8 ± 167; Po0.05) and tea (silybin 1726.6 ± 346.8 versus tea 2099.3 ± 223.3; Po0.05). In conclusion, silybin has the potential to reduce iron absorption, and this deserves further investigation, as silybin could be an adjunct in the treatment of haemochromatosis.
Introduction and methods
In HFE-related hereditary haemochromatosis (HH), dietary iron uptake is increased relative to iron requirements. Treatment of HH involves repeated phlebotomy, which effectively reduces iron stores to maintain them at a normal level. Alternative treatments, if used alongside phlebotomy treatment, would reduce the need for maintenance phlebotomy and would improve the management of HH, particularly in patients with more severe phenotypes. Black tea, a source of iron-binding polyphenols, has been shown to cause a small reduction in both iron absorption and the rate of iron reaccumulation in HH (Kaltwasser et al., 1998) . The polyphenol silybin is found in milk thistle (Silibum marianum), and it is purported to aid liver function. Silybin has a high affinity for ferric iron, forming an iron-silybin complex (Borsari et al., 2001) . Therefore, anecdotal reports of reduced requirements for maintenance phlebotomy in HH patients taking milk thistle may be attributable to the iron-binding effect of silybin, by reducing non-haem iron absorption. Our objective was to investigate the iron-binding potential of silybin in vivo. This pilot study was approved by King's College Hospital Local Research Ethics Committee (LREC reference: 06/Q0703/56) and the Medicines and Healthcare Regulatory Authority (Eudract number: 2006-002099-16) , and was a registered controlled trial (Current Controlled Trials Ltd. reference: CCT-NAPN-15285). All participants gave their written informed consent to take part in this study. This was a crossover study; all patients received all treatments and in random order. Participants were 10 patients (9 males and 1 female) who were homozygous for the C282Y mutation in HFE, with grade 4 siderosis and fibrosis (n ¼ 7) or cirrhosis (n ¼ 3) on liver biopsy. Patients received phlebotomy treatment to maintain their serum ferritin within the normal range, but were not phlebotomized during the study. Additional patient characteristics are shown in Table 1 . After an overnight fast, on three occasions, blood was taken through an indwelling catheter immediately before and at 0.5, 1, 2, 3 and 4 h after ingestion of a meal. The meal consisted of vegetables in tomato sauce, mashed potato and white bread, and contained 478 kcal energy, 22 g fat, 124 mg vitamin C (Holland et al., 1991) , and 13.9 mg non-haem iron (3.9 mg endogenous and 10 mg added in the form of FeCl 3 solution).
Meals were prepared in one batch and frozen until the evening of the study, then reheated before serving. The FeCl 3 solution was added to the meal after reheating and immediately before serving. On each occasion, the meal was consumed with a different treatment: (1) 200 ml water, (2) 200 ml water and silybin in the form of Legalon Forte 140 mg (Madaus GmbH, Köln, DE, USA) or (3) 200 ml black tea infusion containing 170 mg polyphenols expressed as gallic acid equivalents (Conway et al., 2006) . After the meal, the patients were allowed to consume only water for a period of 4 h. Quantitative analysis of serum iron was performed in King's College Hospital, using the revised method approved by the International Committee for Standardisation in Haematology. Iron absorption, based on the serum iron response after ingestion of the meal, was estimated using a method that had been validated in individuals who were avid for iron (Hoppe et al., 2004; Conway et al., 2006) . This method had been previously applied in a study on HH patients (Hutchinson et al., 2007) . The appearance and clearance of total serum iron was assessed by calculating the area under the serum iron curve (AUC) over the 4 h observation period (AUC 0-4 ). A Wilcoxon non-parametric test for related samples was used for comparison of AUC 0-4 following: (1) silybin versus water, (2) tea versus water and (3) silybin versus tea.
Results and discussion
Consumption of silybin with a meal, compared with water, resulted in a significant reduction in the amount of dietary iron absorbed (Figure 1 ; Po0. 05). On the basis of the findings in vitro, in the neutral pH of the duodenum, silybin could form a complex with unchelated iron in the ferric form (Borsari et al., 2001) , rendering it unavailable for absorption. Likewise, it is recognized that consuming tea with meals reduces the absorption of non-haem iron in healthy individuals, and the potential use of tea as a means of reducing dietary iron absorption in HH has been investigated earlier (Kaltwasser et al., 1998) . However, in our study, tea did not reduce the absorption of iron from a single meal compared with water (P ¼ 0.203), and our results suggest that silybin is more effective at limiting the postprandial increase in serum iron compared with tea (Po0.05). The calculated ascorbic acid content of the test meal was 124 mg (Holland et al., 1991) . Ascorbic acid is a powerful promoter of the absorption of non-haem iron (Cook and Monsen, 1977) , and its presence in a meal has been shown to counteract the iron-binding effect of tea polyphenols (Hurrell et al., 1999) ; indeed, this may have been the case in this study. In contrast, silybin resulted in a significant reduction in the amount of iron absorbed from a single meal, even in the presence of ascorbic acid. A published study reported that the iron-chelating properties of silybin were responsible for a decrease in body iron stores in patients with chronic hepatitis C who had been taking silybin orally for 12 weeks (Bares et al., 2008) , which supports the outcome of our study. Likewise, silybin in conjunction with desferrioxamine may be a more effective means of reducing iron stores in patients with b-thalassaemia, compared with desferrioxamine alone (Gharagozloo et al., 2009 ). In conclusion, our findings suggest that in HH patients 140 mg silybin taken as a single dose with a meal reduces the absorption of non-haem iron. The small number of patients is a limiting factor and a type I statistical error cannot be ruled out. Nevertheless, this is an interesting preliminary finding that deserves further investigation with a larger group of HH patients, as silybin could be a useful adjunct in the treatment of HH.
Conflict of interest
The authors declare no conflict of interest. The iron-chelating potential of silybin C Hutchinson et al
